Author： Brown Karen
Publisher： Informa Healthcare
ISSN： 1474-0338
Source： Expert Opinion on Drug Safety, Vol.1, Iss.3, 2002-09, pp. : 253-267
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Risk–benefit effects of tocolytic therapy
By Pryde Peter G Janeczek Susan Mittendorf Robert
Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. :
Access to resources
Recommend
Tamoxifen a worthwhile investment for women at risk for breast cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 252, 2000-01 ,pp. :
Tamoxifen a worthwhile investment for women at risk for breast cancer
Inpharma, Vol. 1, Iss. 1227, 2000-01 ,pp. :
Risk–benefit effects of implantable contraceptives in women
By Brache V Faundes A Alvarez F
Expert Opinion on Drug Safety, Vol. 2, Iss. 3, 2003-05 ,pp. :
Tamoxifen: long-term benefit in ER-positive breast cancer
Inpharma, Vol. 1, Iss. 1584, 2007-01 ,pp. :